What patellofemoral OA actually is

Patellofemoral osteoarthritis (PFOA) affects a specific part of the knee — the joint formed between the underside of the kneecap (patella) and the groove at the front of the thigh bone (femoral trochlea). It is distinct from the better-known tibiofemoral arthritis, which affects the main load-bearing compartment lower in the joint.

The process begins when the smooth articular cartilage lining this interface starts to soften and fray — a stage commonly called chondromalacia patellae. Rather than being a separate diagnosis, chondromalacia sits at the early end of the same continuum as PFOA: left unmanaged, progressive thinning eventually exposes the underlying bone, and contact between bare bone surfaces is what drives the more severe pain of established disease.

Several factors increase the risk of this wearing process. Trochlear or patellar dysplasia — where the kneecap does not sit cleanly in its groove — creates abnormal contact pressures over years. A previous patellar fracture that disturbed the articular surface, or a history of patellar dislocation, can similarly accelerate cartilage breakdown at that interface.

Because only one compartment is involved, PFOA responds to a more targeted assessment and treatment approach than generalised knee arthritis. Injection placement, physiotherapy focus, and the criteria for considering surgery all differ when the pathology is isolated to the front of the joint — which is why confirming which compartment is affected, through examination and imaging, matters from the outset.

The symptom pattern that distinguishes PFOA

Most people with PFOA notice it first on the stairs — a nagging ache behind or around the kneecap that sharpens on the way down more than up. Squatting, kneeling, and getting out of a low chair all load the same joint, and all tend to reproduce the same pain. Sustained sitting with the knee bent — at a cinema, on a long drive, or at a desk — often produces a stiff, uncomfortable ache that eases within a few minutes of standing and straightening the leg. Clinicians sometimes call this the 'cinema sign', and it is one of the more reliable pointers to the patellofemoral compartment specifically.

Some people also notice a grinding or crunching sensation under the kneecap during movement, or intermittent swelling after activity. The pain is consistently at the front of the knee, not along the inner or outer joint line — a distinction that matters because joint-line pain more often points to the tibiofemoral compartment or the meniscus.

The same symptom pattern can arise from other conditions affecting the front of the knee: patellofemoral pain syndrome, patellar tendinopathy, or prepatellar bursitis. Self-diagnosis is unreliable, and a clinical assessment — combining history, physical examination, and imaging — is needed to identify which structure is actually involved.

One further point worth noting: the degree of pain does not always match the extent of structural change visible on a scan. Significant cartilage wear may produce mild symptoms in some patients, while others with modest imaging findings experience substantial discomfort. Both pieces of information — what the scan shows and what the patient experiences — guide management equally.

Why conservative treatment comes first

Three months of structured conservative care is the recommended starting point before injections are considered — not as a bureaucratic hurdle, but because targeted rehabilitation addresses one of the main mechanical drivers of PFOA directly.

The key word is targeted. Generic quadriceps exercises are less useful here than focused work on the vastus medialis oblique (VMO), the teardrop-shaped muscle on the inner lower thigh. The VMO plays a central role in pulling the kneecap medially as the knee straightens; when it is weak or poorly timed relative to the outer quadriceps, the patella tracks laterally in its groove, concentrating load on one side of the joint surface. VMO-specific physiotherapy — exercises such as terminal knee extensions, step-downs, and side-lying leg work — corrects this imbalance and reduces the abnormal contact pressures that drive pain and cartilage wear. This is one of the reasons the physiotherapy programme for PFOA looks different from a general knee-strengthening plan.

Alongside muscle rebalancing, two further steps reduce the load the joint has to absorb during recovery. Activity modification — temporarily scaling back stair repetitions, deep squats, kneeling, and prolonged sitting with the knee bent — takes the patellofemoral joint out of its most compressed positions while strength improves. Where body weight is a contributing factor, even modest reduction in overall weight translates to a meaningful reduction in the force transmitted through the patellofemoral compartment with every step.

Many patients achieve substantial symptom control within this three-month window and do not need to progress to injection. For those who do, conservative care does not stop — physiotherapy and activity management continue alongside any injection chosen, because injections reduce pain and inflammation but do not correct muscle imbalance or patellar tracking on their own.

Four signs that an injection is the right next step

Four clinical situations tend to indicate that escalation to injection is warranted — and understanding them helps avoid both under- and over-treatment.

The first is when pain itself becomes the obstacle to rehabilitation. If discomfort is severe enough that a patient cannot engage meaningfully with physiotherapy — cutting sessions short, unable to load through the relevant exercises — the programme cannot do its work. In this context, an injection is not a shortcut around physiotherapy; it is what makes physiotherapy possible.

The second is significant impact on daily life and sleep. Symptoms that consistently disrupt sleep, prevent occupational tasks, or substantially limit function despite a genuine trial of conservative care represent a meaningful threshold. Continuing without escalation at this point carries its own risks: deconditioning, altered movement patterns, and progressive loss of confidence in the joint.

Third: an acute flare with significant swelling not settling with rest and anti-inflammatory measures. Visible fluid accumulation around the knee indicates active synovial inflammation, and this scenario is precisely where corticosteroid injection — with its rapid anti-inflammatory effect typically within 48–72 hours — is well-matched.

The fourth criterion, and arguably the most important for patient selection, is what imaging reveals about cartilage state. Injections work best when cartilage is still present to support and lubricate. Mild-to-moderate wear represents the window in which viscosupplementation and cushioning agents are most likely to provide meaningful benefit; as loss approaches near-total, expected benefit diminishes and surgical review becomes the more relevant conversation. A specialist uses imaging as one input alongside symptoms, function, and clinical examination — not as a standalone verdict — which is why structured assessment before any injection is essential rather than optional.

How different injections work — and when each fits

The four main injectable options differ in mechanism, duration, and the patient profiles they suit best.

Corticosteroid acts as a rapid anti-inflammatory, delivering relief within days as described above. Because its effect is temporary — typically lasting weeks to a few months — it is best reserved for flare rescue rather than ongoing management. Repeated short-interval courses are generally avoided given the potential for cartilage-related effects over time.

Hyaluronic acid (viscosupplementation) supplements the knee's natural synovial fluid, improving lubrication and shock absorption between the kneecap and trochlear groove. The benefit builds more gradually but tends to last longer. Two randomised controlled trials address patellofemoral pathology directly: Mekariya et al. (2025) found intra-articular 2% sodium hyaluronate effective for isolated PFOA, and Hart et al. (2019) showed a single HA injection reduced pain and improved function in patients who had previously failed conservative management. Systematic review evidence indicates HA works best when cartilage is still present — mild-to-moderate disease rather than end-stage.

Platelet-rich plasma (PRP) uses concentrated platelets drawn from the patient's own blood to support tissue healing and reduce inflammation. It is typically positioned as a second-line or adjunct option for younger or more active patients who have not responded adequately to corticosteroid or HA, with a regenerative rather than purely palliative rationale.

Arthrosamid® (polyacrylamide hydrogel, PAAG) is a single-injection cushioning agent that integrates into the synovial tissue, providing sustained physical support rather than a pharmacological effect. Published data suggest an average of two to three years of symptom relief from one injection. A 2022 case series documented reduction in patellofemoral bone marrow lesions following a single PAAG injection, supporting its application where patellofemoral involvement is significant. Like HA, it is less suited to near-total bone-on-bone loss.

Whichever option is under consideration, ultrasound guidance is standard practice for patellofemoral injections — ensuring accurate placement behind and around the kneecap, where a blind injection risks missing the target.

A note on evidence: most injection trial data come from broader knee OA populations rather than isolated PFOA. The 2025 Mekariya study represents a meaningful step forward, but head-to-head comparisons between HA, PRP, and PAAG in this specific compartment remain limited. Patient age, activity level, and cartilage stage ultimately guide the choice more than any single trial.

When injections reach their limit

Injections reduce pain and inflammation; they do not reverse cartilage loss that has already occurred. This is not a limitation of any particular product — it is a property of the tissue itself. Setting a realistic ceiling on what any injection can achieve is part of making the decision honestly.

For most patients, that ceiling is enough. Symptom control across one or more cycles, supported by ongoing physiotherapy, preserves function and holds more invasive intervention at bay. The problem arrives when each cycle provides shorter and shallower relief, or when imaging and symptoms together indicate that cartilage loss has progressed to near-total. At that point, surgical assessment becomes the more relevant conversation.

Two surgical pathways apply to isolated PFOA, and they differ substantially in scale. Patellofemoral arthroplasty replaces only the front compartment — the kneecap surface and the trochlear groove — leaving the rest of the knee intact. It is appropriate when disease is genuinely confined to that compartment. Total knee arthroplasty, which resurfaces all three compartments, is reserved for patients whose arthritis has spread more widely beyond the patellofemoral joint. The distinction matters: surgery for PFOA does not automatically mean the most extensive procedure available.

The right time to seek a specialist opinion is not necessarily when injections have been exhausted. Mapping the full pathway early — understanding which surgical option would apply, and under what circumstances — means that if injections do reach their limit, the next step is a planned one rather than a reactive default.

1. [1] Chondromalacia Patellae — Wikipedia. https://en.wikipedia.org/?curid=1944613 https://en.wikipedia.org/?curid=1944613
2. [2] Patellofemoral Pain Syndrome — Wikipedia. https://en.wikipedia.org/?curid=12033023 https://en.wikipedia.org/?curid=12033023